Categories
Tags
Abbott Advertising AstraZeneca Barack Obama Biotechnology and Pharmaceuticals Breast cancer Bristol Myers Squibb business Cancer Clinical trial Conditions and Diseases Deal Eli Lilly European Commission European Union FDA Food and Drug Administration Genentech generics GlaxoSmithKline Google GSK HBA Health Health care Johnson & Johnson layoffs Lilly Margaret Hamburg Marketing Merck Novartis Pfizer Pharma Pharmaceutical drug pharmaceutical industry Research and development Roche Sanofi-Aventis Schering Plough social media Twitter U.S. Food and Drug Administration United States Wyeth
Technology News
BioPharm News- Shire Gains European Approval for its Gaucher Disease Treatment
- Mtech Bioprocess Scale-Up Facility to Double in Staff and Size
- ImClone Closes Plant in New Jersey, Consolidating Erbitux Manufacture
- EMA and FDA Seek Applicants for Joint GMP Inspections
- ATMI Expands Bloomington, Minnesota Manufacturing Facility
Clinical Trials News- CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems
- ACR Image Metrix Establishes Global Presence
- BioPharm Systems Named to the 2010 Inc. 500|5000 List of Fastest-Growing Companies in the U.S.
- CRF Health Doubles North American Headquarters
- Oracle Completes Acquisition of Phase Forward
Blogroll
-
Meta
Category Archives: Legal
Mass Gift Ban Repeal Efforts Fizzle
An effort in the Massachusetts legislature to repeal the state’s ban on many gifts to healthcare providers has failed. The year-old ban is considered one of the most restrictive in the country, banning restaurant meals, various gifts and requiring reporting on transfers of value above $50.
“This repeal effort was started by legislators concerned that the [...]
Posted in Legal Tagged business, Food and Drug Administration, Health care, health insurance, Law, Massachusetts, Prescription drug, United States Leave a comment
Avandia on Trial
The mid-July FDA advisory committee meeting to decide the fate of GlaxoSmithKline’s Avandia (rosiglitazone) is widely viewed as a test case of how the agency’s new leadership will address controversial drugs with serious risks but confusing data. A request that GSK yank its diabetes blockbuster—three years after first being associated with an increased risk of [...]
AZ Celebrates Crestor Patent Win
The US District Court in Delaware upheld AstraZeneca’s patent for its blockbuster statin Crestor (rosuvastatin), ending a dispute that could have crippled the drugmaker’s billion-dollar cash cow.
Crestor’s patent is not scheduled to expire until 2016. However, a group of generics firms had claimed that a substance patent (314) protecting one of the active ingredients in [...]
Government Crackdown on the C-Suite
Over the past decade, the drug industry has paid tens of billions of dollars to settle state and federal lawsuits involving the False Claims Act—defrauding Medicare and Medicaid, promoting drugs for unapproved uses, paying kickbacks to doctors and pharmacies, and the like. Stories about off-label promotion of drugs with serious adverse effects and no proven [...]
Posted in Legal Tagged C-Suite, False Claims Act, healthcare fraud, Medicaid, Medicare, OIG Leave a comment

Patients Want to Talk. Do You?